By Jan Wolfe

(Reuters) – A U.S. appeals court on Friday upheld a ruling that canceled patents owned by Teva Pharmaceutical Industries Ltd on its blockbuster multiple sclerosis drug Copaxone.

The ruling was a victory for a group of generic drug companies, including Mylan NV, that challenged the validity of Teva’s patents in order to sell generic versions.

(Reporting by Jan Wolfe; Editing by Bernadette Baum)